Eli Lilly stock rises after FDA approves Inluriyo combo

Published on 09/21/2026 at 14:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eli Lilly stock gained after the FDA approved Inluriyo plus Verzenio on September 18, 2026. Quarterly EPS was $8.38, and revenue reached $22.97 billion.

Extreme Makroaufnahme eines hochpolierten Edelstahlflanschs mit O-Ring-Dichtung einer Vakuumkammer auf schwarzem Hintergrund — Lam Research US5324571083 Makro polierter Vakuumkammer Flansch mit O Ring Dichtung auf schwarzem Hintergrund, Illustration mit AI erstellt.

Eli Lilly and Company stock (ISIN US5324571083) gained after the U.S. FDA granted full approval to Inluriyo plus Verzenio on September 18, 2026, with the combination showing median progression-free survival of 11.1 months versus 5.5 months for Inluriyo alone, according to BioSpace. On the same day, MarketBeat said Lilly had a consensus rating of Moderate Buy and an average target price of USD 1,305.25.

FDA approval adds fresh momentum

BioSpace said the approval covered adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer and was based on the Phase 3 EMBER-3 trial. The company said Inluriyo plus Verzenio doubled median progression-free survival to 11.1 months from 5.5 months, a quantified edge that makes the oncology update the clearest current catalyst for the stock.

MarketBeat also said on September 21, 2026 that Lilly's FY2026 EPS estimate at Erste Group Bank was lifted to USD 36.45 from USD 36.35, while the consensus stood at USD 36.54. The same report put Lilly's own FY2026 guidance at USD 35.50 to USD 36.50 per share, giving the stock a fresh benchmark against a narrow guidance range.

Guidance stays tight

MarketBeat said Lilly reported quarterly EPS of USD 8.38 versus USD 6.40 expected, and revenue of USD 22.97 billion versus USD 20.82 billion expected. It also cited a 47.7 percent year-over-year revenue increase, plus a net margin of 33.53 percent and return on equity of 97.83 percent, which keeps the latest earnings release at the center of valuation debate.

On the analyst side, MarketBeat reported that Berenberg set a USD 1,400.00 price target on September 15, 2026 and that Morgan Stanley reiterated an Overweight rating with a USD 1,419.00 target on August 6, 2026. The average target price across the MarketBeat data set was USD 1,305.25, below both of those house views.

Stock near its high

As of September 18, 2026, Eli Lilly stock closed at USD 1,152.93 on Nasdaq, after trading between USD 1,140.27 and USD 1,157.60 that day, with volume of 4.55 million shares. The same price sits close to the 52-week high of USD 1,292.65 and far above the 52-week low of USD 712.05.